Regulus Therapeutics Inc logo

Regulus Therapeutics Inc Share Price Today (NASDAQ: RGLS)

Regulus Therapeutics Inc share price is $8.18 & ₹697.67 as on 23 Jun 2025 IST

$8.18

▲

0.04

(0.49%)

Market is closed - opens 7 PM, 07 Jul 2025

Bell Icon

The stock has been delisted from the stock exchange on 24 Jun 2025

View live Regulus Therapeutics Inc share price in Dollar and Rupees. Guide to invest in Regulus Therapeutics Inc stock from India, including Indian investor sentiment. Get details on Indian mutual funds investing in Regulus Therapeutics Inc, along with analyst recommendations, forecasts, and comprehensive financials.

Regulus Therapeutics Inc (RGLS) Key Statistics

in dollars & INR

Previous Close
$8.14
Open
$8.16
Market Capitalization
$565.0M
Today's Volume
$9.3M
Revenue TTM
$5.0M
EBITDA
$-51.4M
Earnings Per Share (EPS)
$-0.68
Profit Margin
0.0%
Quarterly Earnings Growth YOY
0.0%
Return On Equity TTM
-53.82%

How to invest in Regulus Therapeutics Inc Stock (RGLS) from India?

It is very easy for Indian residents to invest directly in Regulus Therapeutics Inc from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Regulus Therapeutics Inc stock in both Indian Rupees (INR) and US Dollars (USD). Search for Regulus Therapeutics Inc or RGLS on the INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Regulus Therapeutics Inc or rupee/ dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Regulus Therapeutics Inc shares which would translate to 0.104 fractional shares of Regulus Therapeutics Inc as of today. Learn more about fractional investing.

Indians can now also easily transfer and add money to their US stocks account via the INDmoney app. Invest in US Stocks from India , including recognised companies like Regulus Therapeutics Inc, in just a few clicks!

Global Institutional Holdings in Regulus Therapeutics Inc

  • Federated Hermes Inc

    22.85%

  • NEA Management Company, LLC

    9.34%

  • Octagon Capital Advisors LP

    6.70%

  • BlackRock Inc

    6.02%

  • Vanguard Group Inc

    5.71%

  • Deep Track Capital, LP

    4.71%

Analyst Recommendation on Regulus Therapeutics Inc

Rating
Trend

Buy

    80%Buy

    20%Hold

    0%Sell

Based on 10 Wall street analysts offering stock ratings for Regulus Therapeutics Inc(by analysts ranked 0 to 5 stars)

About Regulus Therapeutics Inc

Regulus Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. The company develops farabursen, an anti-miR oligonucleotide targeting miR-17 in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease. It is also developing a pipeline of preclinical drug products for target organ-selective delivery strategies. The company has a license and collaboration agreement with Alnylam Pharmaceuticals, Inc. and Ionis Pharmaceuticals, Inc. to develop, manufacture, and commercialize products covered by the licensed patent rights for use in microRNA compounds. Regulus Therapeutics Inc. was incorporated in 2007 and is headquartered in San Diego, California.
Organization
Regulus Therapeutics Inc
Employees
34
CEO
Mr. Joseph P. Hagan M.B.A.
Industry
Health Technology

Management People of Regulus Therapeutics Inc

NameTitle
Mr. Joseph P. Hagan M.B.A.
CEO & Director
Dr. Preston S. Klassen M.D., M.H.S.
President, Head of Research & Development and Director
Ms. Crispina Calsada CPA
Chief Financial Officer
Mr. Daniel J. Penksa
VP of Finance & Controller
Mr. Christopher Ray Aker J.D.
Senior VP, General Counsel & Corporate Secretary
Dr. Claire Susan Padgett M.S., M.T., Ph.D.
Senior Vice President of Clinical Operations
Dr. Rekha Garg M.D., M.S.
Chief Medical Officer
Mr. Edmund Lee Ph.D.
Vice President of Translational Medicine

Important FAQs about investing in RGLS Stock from India :

Can Indians buy Regulus Therapeutics Inc shares?

Yes, Indians can invest in the Regulus Therapeutics Inc (RGLS) from India.

With INDmoney, you can buy Regulus Therapeutics Inc at 0 brokerage. The step-by-step process is as follows:

  • Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
  • Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
  • Once funds are transferred successfully, you can buy Regulus Therapeutics Inc at zero transaction cost.

How can I buy Regulus Therapeutics Inc shares from India?

It is very easy to buy Regulus Therapeutics Inc from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Regulus Therapeutics Inc (RGLS) be purchased?

Yes, you can buy fractional shares of Regulus Therapeutics Inc with INDmoney app.

What are the documents required to start investing in Regulus Therapeutics Inc stocks?

To start investing in Regulus Therapeutics Inc, You will need the following documents:

  • Proof of Identification (PAN, Aadhaar etc)
  • Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.

What is today's market capitalisation of Regulus Therapeutics Inc?

Today's market capitalisation of Regulus Therapeutics Inc RGLS is 563.6M

Who is the Chief Executive Officer (CEO) of Regulus Therapeutics Inc ?

Mr. Joseph P. Hagan M.B.A. is the current Chief Executive Officer (CEO) of Regulus Therapeutics Inc.